Archive by category | Industry

FDA revokes approval of breast cancer drug

FDA revokes approval of breast cancer drug

It’s finally official: the US Food and Drug Administration (FDA) has withdrawn its approval of the drug Avastin (bevacizumab) to treat advanced breast cancer. Avastin retains its approval for some other colon, kidney, and brain cancers.

A Canadian rescue for The Scientist?

A Canadian rescue for The Scientist?

The Scientist may not be hanging up its lab coat just yet. Just one week after announcing it was shutting down, the possibility of new ownership has revived hopes that the quarter century-old publication which caters to life scientists will continue on with its editorial team intact.

Siemens pulls the plug on nuclear

Siemens pulls the plug on nuclear

The German company Siemens is pulling out of nuclear power for good. In an interview with der Spiegel published on 18 September, CEO Peter Löscher announced that the company would no longer build or finance nuclear power plants in Germany or anywhere else (English version). Löscher said the decision was in large part due to the accident at Fukushima Daiichi and the German government’s decision to shut down its existing nuclear plants by 2022.

Explosion rocks French nuclear site

Update 16:27 BST: SOCODEI says that the accident is now fully under control and that no radioactive material has been released (download statement).

An explosion has rocked a nuclear waste facility in Southern France, killing 1 and injuring four others. The blast occurred shortly before noon local time, and the ensuing fire was under control as of 13:06 CET. No radioactivity has been released beyond the site, according toe Sabine Mezard, a spokesperson for EDF, which oversees the facility. The French Nuclear Safety Authority (ASN) is allready investigating the accident.

Melanoma drug gets speedy approval

A cancer drug that yielded remarkable results against a seemingly intractable disease has earned an early approval from the US Food and Drug Administration (FDA). Today, regulators announced that vemurafenib (the drug formerly known as PLX4032) will be available for use against advanced melanomas that have a mutated B-RAF protein.

Senator urges White House not to weaken research conflict rule

Senator urges White House not to weaken research conflict rule

The US Senate’s leading advocate for government transparency wrote today to the White House’s budget office, demanding that it protect a proposed rule that would obligate universities to post their publicly-funded biomedical researchers’ financial conflicts on a publicly accessible website.  Read more